Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 19.76
PIP's Cash to Debt is ranked higher than
71% of the 1248 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. PIP: 19.76 )
PIP' s 10-Year Cash to Debt Range
Min: 0.03   Max: No Debt
Current: 19.76

Equity to Asset 0.78
PIP's Equity to Asset is ranked higher than
81% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. PIP: 0.78 )
PIP' s 10-Year Equity to Asset Range
Min: -0.53   Max: 0.8
Current: 0.78

-0.53
0.8
F-Score: 3
Z-Score: 0.04
M-Score: -3.87
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -105.14
PIP's Operating margin (%) is ranked higher than
71% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.88 vs. PIP: -105.14 )
PIP' s 10-Year Operating margin (%) Range
Min: -873.96   Max: 55.46
Current: -105.14

-873.96
55.46
Net-margin (%) -97.77
PIP's Net-margin (%) is ranked higher than
72% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.05 vs. PIP: -97.77 )
PIP' s 10-Year Net-margin (%) Range
Min: -909.98   Max: 47.27
Current: -97.77

-909.98
47.27
ROE (%) -104.94
PIP's ROE (%) is ranked higher than
58% of the 1143 Companies
in the Global Biotechnology industry.

( Industry Median: -35.75 vs. PIP: -104.94 )
PIP' s 10-Year ROE (%) Range
Min: -453.67   Max: -27.07
Current: -104.94

-453.67
-27.07
ROA (%) -64.77
PIP's ROA (%) is ranked higher than
60% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: -28.24 vs. PIP: -64.77 )
PIP' s 10-Year ROA (%) Range
Min: -111.46   Max: -15.19
Current: -64.77

-111.46
-15.19
ROC (Joel Greenblatt) (%) -3246.66
PIP's ROC (Joel Greenblatt) (%) is ranked higher than
60% of the 1223 Companies
in the Global Biotechnology industry.

( Industry Median: -438.40 vs. PIP: -3246.66 )
PIP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -847.79   Max: -186.46
Current: -3246.66

-847.79
-186.46
Revenue Growth (3Y)(%) -18.60
PIP's Revenue Growth (3Y)(%) is ranked higher than
68% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. PIP: -18.60 )
PIP' s 10-Year Revenue Growth (3Y)(%) Range
Min: -30.1   Max: 173.4
Current: -18.6

-30.1
173.4
EBITDA Growth (3Y)(%) -32.60
PIP's EBITDA Growth (3Y)(%) is ranked higher than
60% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. PIP: -32.60 )
PIP' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -66.7   Max: -24.5
Current: -32.6

-66.7
-24.5
EPS Growth (3Y)(%) -40.30
PIP's EPS Growth (3Y)(%) is ranked higher than
58% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. PIP: -40.30 )
PIP' s 10-Year EPS Growth (3Y)(%) Range
Min: -64.7   Max: -9.1
Current: -40.3

-64.7
-9.1
» PIP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

PIP Guru Trades in Q4 2013

Jim Simons 40,500 sh (-72.32%)
» More
Q1 2014

PIP Guru Trades in Q1 2014

Jim Simons 21,700 sh (-46.42%)
» More
Q2 2014

PIP Guru Trades in Q2 2014

Jim Simons Sold Out
» More
Q3 2014

PIP Guru Trades in Q3 2014

Louis Moore Bacon 50,000 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with PIP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 5.75
PIP's P/B is ranked higher than
75% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 6.13 vs. PIP: 5.75 )
PIP' s 10-Year P/B Range
Min: 1.3   Max: 31.64
Current: 5.75

1.3
31.64
P/S 8.00
PIP's P/S is ranked higher than
85% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 28.86 vs. PIP: 8.00 )
PIP' s 10-Year P/S Range
Min: 0.44   Max: 103.75
Current: 8

0.44
103.75
EV-to-EBIT -7.75
PIP's EV-to-EBIT is ranked lower than
55% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. PIP: -7.75 )
PIP' s 10-Year EV-to-EBIT Range
Min: -16.6   Max: 199.6
Current: -7.75

-16.6
199.6
Current Ratio 5.30
PIP's Current Ratio is ranked higher than
75% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.74 vs. PIP: 5.30 )
PIP' s 10-Year Current Ratio Range
Min: 0.41   Max: 389.51
Current: 5.3

0.41
389.51
Quick Ratio 5.30
PIP's Quick Ratio is ranked higher than
76% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. PIP: 5.30 )
PIP' s 10-Year Quick Ratio Range
Min: 0.41   Max: 389.51
Current: 5.3

0.41
389.51

Valuation & Return

vs
industry
vs
history
Price/Net Cash 7.36
PIP's Price/Net Cash is ranked higher than
86% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 50.00 vs. PIP: 7.36 )
PIP' s 10-Year Price/Net Cash Range
Min: 3.26   Max: 186
Current: 7.36

3.26
186
Price/Net Current Asset Value 7.08
PIP's Price/Net Current Asset Value is ranked higher than
85% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 29.38 vs. PIP: 7.08 )
PIP' s 10-Year Price/Net Current Asset Value Range
Min: 2.84   Max: 211.5
Current: 7.08

2.84
211.5
Price/Tangible Book 6.58
PIP's Price/Tangible Book is ranked higher than
78% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9.38 vs. PIP: 6.58 )
PIP' s 10-Year Price/Tangible Book Range
Min: 1.48   Max: 37
Current: 6.58

1.48
37
Price/Median PS Value 2.67
PIP's Price/Median PS Value is ranked higher than
73% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. PIP: 2.67 )
PIP' s 10-Year Price/Median PS Value Range
Min: 0.22   Max: 34.17
Current: 2.67

0.22
34.17
Earnings Yield (Greenblatt) -12.90
PIP's Earnings Yield (Greenblatt) is ranked higher than
63% of the 1218 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. PIP: -12.90 )
PIP' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.5   Max: 0.9
Current: -12.9

0.5
0.9

Business Description

Industry: Biotechnology » Biotechnology
Compare:NONOF, AMGN, GILD, BIIB, CELG » details
PharmAthene, Inc. was incorporated under the laws of the State of Delaware on April 25, 2005. It is a biodefense company, which is engaged in the development and commercialization of medical countermeasures against biological and chemical weapons. Its biodefense portfolio includes the product candidates namely SparVax, a second generation recombinant protective antigen (rPA) anthrax vaccine; Valortim, a fully human monoclonal antibody for the prevention and treatment of anthrax infection, and; rBChE (recombinant butyrylcholinesterase) bioscavanger, a medical countermeasure for nerve agent poisoning by organophosphorous compounds, including nerve gases and pesticides. The Company's customers are the U.S. Department of Defense (the DoD), the National Institute of Allergy and Infectious Diseases ('NIAID), and the National Institute of Health (NIH). The Company is subject to various federal, state and local laws, regulations and recommendations relating to safe working conditions, laboratory and manufacturing practices, the experimental use of animals, and the use and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with its various activities.
» More Articles for PIP

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: BWEN, ENZ, PIP, HAFC, AACC Nov 21 2011 
PharmAthene Inc (PIP) CEO Eric I Richman buys 10,000 Shares Jun 21 2010 
Guru Activities for Today’s Price % Losers: PharmAthene Inc. , Authentidate Holding Corp., Kroger Dec 08 2009 

More From Other Websites
PharmAthene Fulfills Valortim® IDIQ Contract Nov 20 2014
PharmAthene Fulfills Valortim® IDIQ Contract Nov 20 2014
PHARMATHENE, INC Financials Nov 15 2014
10-Q for PharmAthene, Inc. Nov 08 2014
PHARMATHENE, INC Files SEC form 10-Q, Quarterly Report Nov 06 2014
PHARMATHENE, INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 06 2014
PharmAthene Provides Third Quarter 2014 Operational And Financial Update Nov 06 2014
PharmAthene Provides Third Quarter 2014 Operational And Financial Update Nov 06 2014
PharmAthene Announces U.S. Bankruptcy Court Partially Lifts Litigation Stay To Permit Delaware Court... Oct 08 2014
PHARMATHENE, INC Files SEC form 8-K, Other Events Sep 19 2014
Siga Bankruptcy Hearing Too Soon for Suit Fight: Judge Sep 17 2014
Biodefense drugmaker Siga files for bankruptcy Sep 16 2014
Siga, Smallpox Drug Supplier to U.S., Files Bankruptcy Sep 16 2014
PHARMATHENE, INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD... Sep 12 2014
PharmAthene Awarded Contract Of Up To $28.1 Million To Develop Next Generation Thermostable Anthrax... Sep 10 2014
New Non-Clinical Data Demonstrate SparVax® Provides Equivalent Protection In Head-To-Head... Sep 09 2014
PharmAthene To Present At Rodman & Renshaw And Aegis Capital Corporation 2014 Investment Conferences Sep 08 2014
PharmAthene and Nanotherapeutics Form Strategic Alliance to Advance Biodefense Programs Sep 08 2014
Jazz Pharmaceuticals (JAZZ) in Focus: Stock Surges 8.8% Aug 14 2014
PharmAthene May Get $500 Million From Smallpox Drug Sales Aug 12 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK